T-DXd is effective after T-DM1

The antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) is a highly effective second-line therapy for patients with metastatic HER2-positive breast cancer. Nonetheless, the activity of this agent in patients with disease progression on trastuzumab emtansine (T-DM1), the previous second-line standard of care, remains unknown. Now, data from the phase III DESTINY-Breast02 trial provide evidence supporting the use of T-DXd in this setting.

留言 (0)

沒有登入
gif